CDXS Earnings Date: Nov 5, 2026 (Estimated) — Codexis, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CDXS's next earnings date?
Codexis, Inc. (CDXS) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10 on revenue of $18.7M.
How did CDXS do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Codexis, Inc. posted EPS of -$0.13 versus the -$0.14 estimate, a beat of 0.0%. Revenue was $14.9M against a $13.8M estimate. The stock's 1-day post-earnings move was +8.1%.
How much does CDXS stock move after earnings?
CDXS beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.6% (up or down) in the day after earnings.
About Codexis, Inc.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.14 | -0.13 | +0.00% | $14.9M | ✅ Beat | +8.11% | +1.35% | -2.70% |
| 2026-05-07 | Q1 2026 | -0.11 | -0.10 | +9.09% | $15.2M | ✅ Beat | +10.47% | -0.39% | +0.97% |
| 2026-03-11 | Q4 2025 | -0.04 | 0.11 | +375.00% | $38.9M | ✅ Beat | +34.65% | +15.75% | +76.38% |
| 2025-11-06 | Q3 2025 | -0.14 | -0.22 | -57.14% | $8.6M | ❌ Miss | -16.95% | -19.90% | -5.65% |
| 2025-08-13 | Q2 2025 | -0.16 | -0.16 | +200.00% | $15.3M | ➖ Inline | +1.64% | -7.54% | -20.33% |
| 2025-02-27 | Q4 2024 | -0.02 | -0.13 | -550.00% | $21.5M | ❌ Miss | -22.65% | -30.53% | -28.50% |
| 2024-10-31 | Q3 2024 | -0.24 | -0.29 | -20.83% | $12.8M | ❌ Miss | +11.46% | +33.12% | +50.32% |
| 2024-08-08 | Q2 2024 | -0.27 | -0.32 | -18.52% | $8.0M | ❌ Miss | -11.11% | -10.79% | -16.83% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $14.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 88.6% | $13.2M | +79.1% | $25.6M | $6.1M | $7.4M | $6.8M |
| Research and Development Revenue | 11.4% | $1.7M | -78.6% | $20.9M | — | $7.9M | $1.8M |
By region
Q2 FY26 · $14.9M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| APAC | 78.7% | $11.7M | +78.4% | — | $1.5M | $6.6M | $6.1M |
| Americas | 11.5% | $1.7M | -72.9% | $12.5M | $2.1M | $6.4M | $1.6M |
| EMEA | 9.7% | $1.5M | -39.4% | $5.6M | $3.9M | $2.4M | $972K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.